Impax, Dr. Reddy’s settle dispute over generic Rytary
Impax Laboratories and Dr. Reddy’s have settled their patent infringement dispute over Rytary, a medication used to treat Parkinson’s disease.
Impax Laboratories and Dr. Reddy’s Laboratories have reportedly settled their patent infringement dispute concerning the sale of a generic medication for Parkinson’s disease.
Impax and Dr. Reddy’s have agreed to voluntarily dismiss all allegations and counterclaims, per a bloomberglaw.com report which cited a stipulation filed Feb. 7 in the U.S. District Court for the District of New Jersey.
The parties have “agreed to terms and conditions for a settlement of this action,” according to the filing.
In July, Impax sued Dr. Reddy’s and its American unit in July, alleging it was planning to sell a drug similar to Impax’s Rytary.
[Read more: Dr. Reddy’s, Senores Pharmaceuticals launch generic Stromectol]
